Durable molecular remission in a patient with relapsed NPM1/IDH1 mutant acute myeloid leukemia treated with venetoclax combined with azacitidine: a case report.
10.3760/cma.j.issn.0253-2727.2022.02.017
- Author:
Xiao Hong LIU
1
;
Ying WU
1
;
Xiao Jun HUANG
1
;
Hao JIANG
1
Author Information
1. Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Azacitidine/therapeutic use*;
Bridged Bicyclo Compounds, Heterocyclic/therapeutic use*;
Humans;
Isocitrate Dehydrogenase/therapeutic use*;
Leukemia, Myeloid, Acute/genetics*;
Nuclear Proteins;
Sulfonamides
- From:
Chinese Journal of Hematology
2022;43(2):166-166
- CountryChina
- Language:Chinese
